Nottingham, UK – In a monumental leap forward for oncology, scientists and clinicians in Nottingham have unveiled an ultra-rapid method for genetically diagnosing brain tumours, poised to revolutionise patient care across the UK. This groundbreaking innovation promises to condense a harrowing diagnostic waiting period of 6-8 weeks down to a mere two hours, potentially transforming the lives of thousands of patients each year by enabling faster, more precise treatment.
Developed by a collaborative team at the University of Nottingham and Nottingham University Hospitals NHS Trust (NUH), this pioneering technique, detailed in a new study published today in the prestigious journal Neuro-Oncology, represents a paradigm shift in the battle against one of the most aggressive and challenging forms of cancer.
Main Facts: A Race Against Time Accelerated
The core of this medical breakthrough lies in its unprecedented speed and accuracy. Traditionally, diagnosing brain tumours, particularly in classifying their specific genetic makeup, has been a protracted and emotionally taxing process for patients and their families. Samples collected during surgery would embark on a journey to centralised analysis facilities, often taking over a month, sometimes two, to yield comprehensive results. This agonizing wait not only amplifies patient anxiety but crucially delays the initiation of vital treatments like radiotherapy and chemotherapy, potentially compromising their effectiveness.
The Nottingham team’s new method bypasses these delays entirely. By employing advanced genetic sequencing techniques directly within the hospital environment, clinicians can now obtain a detailed tumour classification within minutes of sequencing, and a full diagnostic result in under two hours from the moment surgery concludes. This astonishing turnaround time offers the tantalising prospect of informing surgical strategy during the operation itself, allowing surgeons to make real-time, data-driven decisions that could significantly impact patient outcomes.
During a series of 50 brain tumour surgeries at NUH, the new approach was rigorously tested, achieving a flawless 100% success rate. Diagnostic results were consistently delivered within the two-hour window, with a fully integrated diagnosis available within 24 hours due to the platform’s continuous sequencing capabilities. This success rate underscores the robustness and reliability of the new system, positioning it as a transformative tool in neuro-oncology.
This innovation is not just about speed; it also promises enhanced diagnostic accuracy and cost-effectiveness. By integrating multiple diagnostic analyses into a single, rapid test, the new method streamlines a previously fragmented and expensive process, making advanced genetic profiling more accessible and efficient.
Chronology of a Revolution: From Weeks to Minutes
The journey to this rapid diagnostic capability is a testament to years of dedicated research, building upon significant advancements in genomic sequencing technology. Understanding the context of the traditional diagnostic pathway highlights the magnitude of this achievement.
The Traditional Bottleneck:
For decades, the diagnostic pathway for suspected brain tumours began with an MRI scan to identify the presence and location of a mass. Following initial consultations with clinicians, patients would often undergo surgery to obtain a tumour sample. This sample was then dispatched to specialised, centralised laboratories for detailed pathological examination.
Historically, neuropathologists would primarily rely on visual inspection of tissue specimens under a microscope to identify cell types and morphological characteristics. However, the last few years have witnessed a profound shift in brain tumour classification. The World Health Organization (WHO) now mandates that brain tumours be categorised not just by their appearance but fundamentally by their underlying DNA and genetic abnormalities. This molecular profiling is crucial because different genetic mutations dictate distinct tumour behaviours, prognoses, and responses to specific therapies.
While genetically informed diagnosis offered superior precision, it introduced a significant logistical challenge: the need for complex molecular tests. These tests, requiring specialised equipment and expertise, were typically performed in a few central facilities, leading to the infamous 6-8 week waiting period. This protracted wait meant patients and their families endured immense psychological distress, grappling with uncertainty while potentially aggressive tumours continued to grow unchecked, delaying the commencement of potentially life-saving treatments like radiotherapy and chemotherapy.
The Genesis of the Solution: Professor Loose’s Vision:
The impetus for this radical acceleration came from Professor Matt Loose, a brilliant biologist from the School of Life Sciences at the University of Nottingham. Professor Loose developed a novel method leveraging Oxford Nanopore Technologies’ portable sequencing devices. His innovation focused on sequencing specific, relevant parts of human DNA at higher depth, rather than the entire genome. This targeted approach allowed for much quicker analysis, enabling multiple regions of DNA to be sequenced simultaneously, thus dramatically speeding up the entire process.
Professor Loose recounted the arduousness of earlier genomic efforts: "When we first were able to sequence an entire human genome in 2018, it took around five labs and six months to do, which obviously isn’t ideal when time is of the essence for a patient." His subsequent research refined this, allowing scientists to pinpoint and examine only the crucial genomic segments pertinent to tumour classification.
Introducing ROBIN: The Technological Engine:
The practical application of Professor Loose’s method culminated in the development of ROBIN, a sophisticated software tool designed to work with P2 PromethION nanopore sequencers. The technology behind ROBIN is elegantly simple yet incredibly powerful: it sequences DNA by detecting minute changes in electrical current as single DNA molecules pass through a nanopore – a tiny, protein-based hole embedded in a membrane. Each nucleotide (the building blocks of DNA) creates a unique electrical signature, allowing the device to read the DNA sequence in real-time.
This direct, real-time sequencing capability is a major departure from older methods that involved amplification and optical detection, which added significant time and complexity. "This new method now allows us to choose the bits of DNA that we need to look at in order to answer specific questions, such as what type of tumour and how can it be treated," Professor Loose explained. "Combined with our later research where we were able to look at relevant parts of the human genome more quickly – then we now have a process where we can use ROBIN to create comprehensive classifications of tumours more quickly."
The Intraoperative Advantage:
Once a tumour sample is removed during surgery, it is immediately sent to the pathology lab where DNA is extracted. This DNA is then passed to Professor Loose’s team for sequencing using the ROBIN platform. The critical diagnostic marker they focus on early in the process is methylation. Methylation patterns – chemical modifications to DNA that don’t alter the sequence but control gene activity – are incredibly informative for defining brain tumour types and subtypes with high precision. "Methylation is the one we are most interested in early on in this instance because that defines the tumour type," Professor Loose confirmed.
The ability to perform this complex genetic analysis within hours means that for the first time, surgeons could potentially receive crucial diagnostic information during an ongoing operation. Dr. Stuart Smith, a Neurosurgeon from the School of Medicine at the University and within NUH, highlighted this unprecedented advantage: "This type of operation can be quite long, so potentially, a surgeon could be informed during surgery of the accurate diagnosis, which would then impact on the surgical strategy." This real-time feedback loop could guide decisions on the extent of tumour resection or the need for additional biopsies, optimising surgical outcomes from the outset.
Supporting Data: The Urgent Need and Compelling Advantages
The urgency for such a rapid diagnostic tool is underscored by the stark realities of brain tumour incidence and survival rates in the UK.
The Burden of Brain Tumours:
Every single day in the UK, an estimated 34 individuals receive the devastating news of a brain tumour diagnosis. This equates to more than 12,000 new cases each year. Brain tumours are notoriously aggressive, with the average survival rate for the most malignant forms often less than a year. This grim prognosis amplifies the critical importance of swift, accurate diagnosis and immediate treatment initiation.
The Toll of Delay:
The traditional 6-8 week waiting period for comprehensive genetic results imposes an immense psychological burden on patients and their families. Living with the uncertainty of a brain tumour type, its aggressiveness, and prognosis for such an extended period is profoundly traumatic. Beyond the emotional toll, this delay has tangible clinical consequences. Radiotherapy and chemotherapy are most effective when initiated promptly after diagnosis. A prolonged wait can reduce the chances of these treatments working optimally, directly impacting patient survival and quality of life. The new method directly addresses this critical window, ensuring patients receive the right treatment at the right time.
Accuracy and Precision:
Beyond speed, the Nottingham method significantly enhances diagnostic accuracy. Dr. Simon Paine, a Consultant Neuropathologist at NUH, enthusiastically stated, "This new method of diagnosing brain tumours is going to be a game changer, it really is revolutionary. It not only increases the speed at which the results will be available, but the degree of accuracy of the diagnosis as well is incredible." This improved accuracy stems from the detailed molecular profiling, which provides a more granular understanding of the tumour’s biology than traditional histological examination alone.
Economic Efficiency:
In an era of increasing pressure on healthcare budgets, the new diagnostic method also presents a compelling economic advantage. Professor Loose highlighted its cost-effectiveness: "Not only is the test more accurate and quicker, but it is also cheaper than current methods. Our calculations stand at around £450 per person, potentially less when scaled-up." This cost reduction is achieved by consolidating what previously required four to five separate tests into a single, comprehensive analysis. By getting more information from one integrated test, the overall expense is significantly lowered, making advanced molecular diagnostics more sustainable within the NHS. Crucially, as Professor Loose notes, "Most importantly, it delivers results to the patients when they need them," preventing the downstream costs associated with delayed treatment and prolonged patient anxiety.
Official Responses: A Chorus of Acclaim
The development has been met with widespread enthusiasm from clinicians, researchers, and patient advocacy groups, all recognising its profound potential.
Dr. Stuart Smith, Neurosurgeon, University of Nottingham and NUH:
Dr. Smith underscored the clinical and human impact of the innovation: "Traditionally, the process of diagnosing brain tumours has been slow and expensive. Now, with this new technology we can do more for patients because we can get answers so much more quickly which will have a much bigger influence on clinical decision making, in as little as two hours. Patients find waiting many weeks for results extremely difficult and this adds to the anxiety and worry at what is already a very difficult time." His emphasis on intraoperative decision-making reveals the depth of the method’s potential: "This type of operation can be quite long, so potentially, a surgeon could be informed during surgery of the accurate diagnosis, which would then impact on the surgical strategy."
Professor Matt Loose, Biologist, University of Nottingham:
Professor Loose, the scientific architect of the method, articulated the journey from foundational research to clinical application: "When we first were able to sequence an entire human genome in 2018, it took around five labs and six months to do, which obviously isn’t ideal when time is of the essence for a patient. This new method now allows us to choose the bits of DNA that we need to look at in order to answer specific questions, such as what type of tumour and how can it be treated. Combined with our later research where we were able to look at relevant parts of the human genome more quickly – then we now have a process where we can use ROBIN to create comprehensive classifications of tumours more quickly." He further clarified the diagnostic focus: "Once we have a sample from a patient, we can now quickly extract the DNA and look at the different properties to give us the information we need. Methylation is the one we are most interested in early on in this instance because that defines the tumour type." On the economic front, he stated, "Not only is the test more accurate and quicker, but it is also cheaper than current methods. Our calculations stand at around £450 per person, potentially less when scaled-up. There are a few reasons for this. Our method can eliminate the need for four to five separate tests, reducing costs as a consequence as we are getting more information from the single test we do. Most importantly, it delivers results to the patients when they need them."
Dr. Simon Paine, Consultant Neuropathologist, NUH:
Dr. Paine, witnessing the method’s capabilities firsthand in the pathology lab, offered a powerful endorsement: "This new method of diagnosing brain tumours is going to be a game changer, it really is revolutionary. It not only increases the speed at which the results will be available, but the degree of accuracy of the diagnosis as well is incredible." His perspective from the diagnostic frontline highlights the tangible benefits for both clinicians and patients.
Dr. Simon Newman, Chief Scientific Officer, The Brain Tumour Charity:
Representing the patient community, Dr. Newman hailed the development as truly transformative: "The delivery of an accurate diagnosis within hours of surgery will be transformative for all patients ensuring rapid access to the optimal standard of care and – crucially – removing the uncertainty patients face when having to wait weeks for their diagnosis and prognosis." He further elaborated on the broader implications for healthcare equity: "The potential to combine so many separate tests into one and deliver at a localised level is a game changer for driving equity of access to rapid and accurate molecular diagnosis. The BRAIN MATRIX Trial, funded by the Brain Tumour Charity, is now exploring how this technology can match patients to personalised clinical trials across the UK." This statement underscores the strategic importance of localised, integrated diagnostics for equitable access to cutting-edge care.
Implications: A New Era for Brain Tumour Care
The ramifications of Nottingham’s rapid genetic diagnostic method extend far beyond simply shortening a waiting period; they herald a new era in brain tumour management, promising profound improvements across several key domains.
Transforming Patient Experience and Outcomes:
The most immediate and impactful implication is the radical improvement in the patient experience. The emotional burden of waiting weeks for a diagnosis, compounded by the severe prognosis often associated with brain tumours, is immense. By reducing this wait to mere hours, the new method alleviates unimaginable anxiety, allowing patients and their families to receive crucial information swiftly. This enables them to process the diagnosis, understand their prognosis, and participate in informed discussions about treatment options much sooner. Crucially, faster diagnosis means faster initiation of treatment. For aggressive brain cancers where every day counts, this rapid turnaround can literally mean the difference between life and death, significantly improving the chances of treatment efficacy and overall survival rates. It moves patients from a state of prolonged agonizing uncertainty to one of proactive management.
Empowering Clinical Decision-Making:
For clinicians, the ability to obtain detailed genetic information so rapidly is a game-changer. The prospect of informing surgical strategy during an operation is unprecedented. Surgeons can make more precise decisions about the extent of tumour removal, potentially reducing the need for follow-up surgeries or adjusting treatment plans in real-time. Post-surgery, the rapid molecular diagnosis allows oncologists to tailor treatment plans – whether radiotherapy, chemotherapy, or targeted therapies – with unparalleled speed and precision. This moves the field closer to truly personalised medicine, ensuring each patient receives the most effective, genetically-matched therapy without delay. The integrated diagnosis within 24 hours also means that multidisciplinary teams can convene and formulate comprehensive treatment strategies almost immediately, optimising the entire care pathway.
Driving Equity and Accessibility in Molecular Diagnostics:
The current reliance on centralised testing facilities creates geographical and logistical barriers to advanced molecular diagnostics. By developing a method that is not only faster and more accurate but also significantly cheaper and amenable to localised deployment, the Nottingham team is paving the way for greater equity of access. The goal to roll out this new testing across NHS Trusts nationwide indicates a strategic vision to decentralise sophisticated genetic profiling, making it available to more patients, regardless of their location. This local accessibility is vital for ensuring that all patients benefit from rapid and accurate molecular diagnosis, a critical step towards standardising high-quality care across the UK.
Paving the Way for Personalised Trials and Research:
The Brain Tumour Charity’s funding of the BRAIN MATRIX Trial, which aims to match patients to personalised clinical trials across the UK using this technology, highlights another crucial implication. Rapid, accurate molecular profiling is fundamental for stratifying patients for clinical trials, particularly those testing novel targeted therapies. By quickly identifying specific genetic markers, researchers can efficiently recruit eligible patients for trials, accelerating the development and validation of new treatments. This integration of diagnostics with research will undoubtedly propel advancements in brain tumour therapy.
Economic Efficiencies and Sustainability:
The significant cost reduction (£450 per person, potentially less when scaled) is a vital implication for the sustainability of healthcare systems. By replacing multiple, often expensive, individual tests with a single, comprehensive, and rapid assay, the NHS can achieve substantial savings while simultaneously enhancing the quality of care. This demonstrates that cutting-edge technology can also be economically viable, offering a model for future diagnostic developments.
In conclusion, the ultra-rapid genetic diagnosis method for brain tumours developed in Nottingham represents a profound medical advancement. By compressing weeks of anxious waiting into mere hours, it promises to alleviate immense suffering, empower clinicians with unprecedented real-time information, and accelerate the delivery of personalised, life-saving treatments. This is not just an incremental improvement; it is a revolutionary step that will redefine the landscape of brain tumour care, offering renewed hope to thousands of patients and their families across the UK and potentially worldwide.
About the Author
